Horst Domdey

Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies

BioM AG is a regional technology transfer and venture capital services company created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition. The firm provides business support services to Munich-based biotechnology companies, focusing on startups. Through BioM Biotech Cluster Development GmbH, established in 2006, BioM coordinates the Munich Biotech Cluster, with the objective of turning it into a leading biotechnology center in Europe. They seek to foster an active cooperation between Bavarian research institutions and corporations. BioM actively invests seed capital in biotechnology startups in the Munich area, and manages a venture capital investment fund invested in high-growth early-stage businesses.

BMBD is a venture capital investment manager specialized in early-stage biotechnology companies with high-growth potential. The firm invests in Europe with a strong focus on the Munich area. They generally co-invest, often in companies first launched through a seed investment from BioM. BMBD generally acquires minority stakes. Their goal is to accompany their portfolio companies into the later stages of development. In addition to capital, the firm provides business support services leveraging BioM's network and capabilities.

Develops cancer drugs based on nanotechnology for human and veterinary use

Functions as a College/University

Operates as a biomedical research institute

Operates as business association for biotechnology industry

Develops instruments for molecular pathogen detection